- General Statements: All Other Content
- NEW ADVANCED FORMULA NEW POWERFUL FORMULA
- General Statements: All Other Content
- BCAA mTOR ACTIVATION FORMULA MONSTER AMINO PST (Protein Synthesis Threshold) is a concentrated BCAA formula that delivers an 8:1:1 ratio of Leucine to Isoleucine to Valine. Recent university research shows that Leucine enriched beverages consumed with exercise synergistically activate and prolong activity of the mTOR signaling pathway, which increases muscle anabolic potential (muscle growth). 1,2,3 The mTOR pathway is the “trigger” that signals the very genesis of muscle protein synthesis.
(Image)8:1:1 LEUCINE ISOLEUCINE VALINE
MONSTER AMINO is able to achieve the anabolic 8:1:1 BCAA ratio by combining PepForm(TM)Leucine Peptides, and free-form L-Leucine, L-Isoleucine and L-Valine for maximum muscle-building performance.
- Suggested/Recommended/Usage/Directions
- (Image)DIRECTIONS AND USE
As a dietary supplement, mix 1 level scoop (12.5g) of Monster Amino with 8-10 fl-oz of water. Consume 1 serving immediately post-workout. Monster Amino can also be consumed before and during workouts or any time to boost amino acid pools and
nitrogen balance. CytoSport products complement a healthful eating and hydration plan that, when combined with a balanced exercise program, may contribute to healthy weight
management and recovery from exercise. Do not use this product as your sole source of nutrition.
- General Statements: All Other Content
- LEU PepForm(TM) Leucine Peptides LEUCINE PEPTIDES FOR ENHANCED LEUCINE BIOAVAILABILITY TO TRIGGER mTOR PATHWAY MUSCLE PROTEIN SYNTHESIS
VITAMIN B6(PYRIDOXAL-5-PHOSPHATE) AN ESSENTIAL CO-FACTOR THAT HELPS DRIVE METABOLIC REACTIONS NECESSARY FOR BCAA UTILIZATION AT THE CELLULAR LEVEL
CITRULLINE MALATE FOR ENHANCED NITRIC OXIDE SYNTHESES AND NUTRIENT DELIVERY
COMPLETE AMINO ACID PROFILE ESSENTIAL AND NON-ESSENTIAL AMINO ACIDS
- Formulation re: Does NOT Contain
- SUGAR FREE
- General Statements: All Other Content
- 1) Dreyer et al. Am J Physiol Endrocrinol Metab 294:E392-E400 (2008)
2) Fujita et al. J Phuysiologuy 582(2):813-23 (2007)
3) Koopman et al. Am J Physiol Endocrinol Metab 288:E645-53 (2005)
- Brand IP Statement(s) re: (c), (TM), (SM)